心源性休克合并重度二尖瓣反流患者经导管缘对缘二尖瓣修复的结局
器械成功率达85.6%,器械成功与1年全因死亡及心衰住院风险显著降低相关。
要点
- 心源性休克合并重度MR患者TEER器械成功率达85.6%。
- 器械成功与1年全因死亡风险降低相关(调整HR 0.49)。
- 器械成功与1年死亡或心衰住院复合终点降低相关(调整HR 0.51)。
核心结论
- 多数心源性休克合并重度二尖瓣反流患者可实现器械成功,且与1年死亡和心衰住院显著降低相关。
- 仍需随机试验评估TEER在心源性休克中的治疗价值。
研究设计与样本
- 共纳入3797例接受TEER的显著二尖瓣反流合并心源性休克患者。
- 心源性休克定义为编码诊断、使用正性肌力药或TEER前机械循环支持。
- 器械成功定义为MR降低≥1级且最终MR分级≤2+。
- 主要结局为器械成功对1年死亡或心衰再住院的影响,采用Cox比例风险模型进行风险校正。
主要发现
- 患者平均年龄73.0±11.9岁,男性占59.5%。
- 平均STS评分(二尖瓣修复)为14.9%±15.3%。
- MR病因中退行性占53.4%,功能性占27.5%。
- 器械成功3249例(85.6%),最终MR≤2+占88.2%,MR绝对降低≥1级占91.4%。
- 1年时器械成功组全因死亡34.6% vs 55.5%(调整HR 0.49,95%CI 0.41-0.59,P<0.001);死亡或心衰住院复合终点29.6% vs 45.2%(调整HR 0.51,95%CI 0.42-0.62,P<0.001)。
临床怎么用
- 对于合并心源性休克的重度二尖瓣反流患者,TEER实现器械成功与1年死亡及心衰住院风险降低相关。
- 临床决策时可考虑对经过选择的心源性休克合并重度MR患者实施TEER,但需认识到证据来自注册研究。
局限性
- 为注册研究,非随机设计,可能存在残余混杂。
- 心源性休克定义基于编码、药物或机械循环支持,可能存在误分类。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Data on the efficacy of transcatheter edge-to-edge repair (TEER) in patients with cardiogenic shock (CS) are limited. OBJECTIVES: This study investigated the characteristics and outcomes of consecutive patients with significant mitral regurgitation (MR) and CS who underwent TEER. METHODS: The Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry was assessed from November 22, 2013, to December 31, 2021. CS was defined as the coding of: 1) CS; 2) inotrope use; or 3) mechanical circulatory support before TEER. Device success was defined as MR reduction of ≥1 grade and a final MR grade ≤2+. The primary outcome was the impact of device success on 1-year mortality or heart failure (HF) readmissions. Cox proportional hazards models were used to report the risk-adjusted association between device success and 1-year outcomes. RESULTS: A total of 3,797 patients met the inclusion criteria. Mean age was 73.0 ± 11.9 years, and 59.5% were male. Mean Society of Thoracic Surgery score (MV repair) was 14.9% ± 15.3%. MR etiology was degenerative (53.4%) and functional (27.5%). Device success was achieved in 3,249 (85.6%) patients given successful achievement of final MR grade ≤2+ (88.2%) and MR reduction ≥1 absolute grade (91.4%). At 1 year after TEER, device success was associated with significantly lower all-cause mortality (34.6% vs 55.5%; adjusted HR: 0.49; 95% CI: 0.41-0.59; P < 0.001) and a composite of mortality or HF admissions (29.6% vs 45.2%; adjusted HR: 0.51; 95% CI: 0.42-0.62; P < 0.001). CONCLUSIONS: Successful MR reduction is achievable in most patients with CS and is associated with significantly lower mortality and HF hospitalization at 1 year. Randomized trials assessing TEER in CS are needed to establish this potential therapeutic approach.
引用
- Simard, Vemulapalli, Jung, et al. Transcatheter Edge-to-Edge Mitral Valve Repair in Patients With Severe Mitral Regurgitation and Cardiogenic Shock. J Am Coll Cardiol. 2022. PMID: 36126766. doi:10.1016/j.jacc.2022.09.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。